Natco Pharma Limited NATCOPHARM

Latest filings

• Routine15 6 Nov, 16:27 · NSE
  Schedule of meet
• Pledge76 4 Nov, 15:31 · BSE
  The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on November 04, 2026 for V C Nannapaneni
• Insider / SAST45 30 Oct, 10:42 · BSE
  The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Venkaiah Chowdary Nannapaneni
• Board meeting40 29 Oct, 17:20 · BSE
  Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2026 ,inter alia, to consider and approve the Un-audited Financial Results ....
• Routine15 29 Oct, 17:08 · BSE
  News Paper Publication for Basis of Allotment of Right Issue
• Fund raising72 23 Oct, 21:05 · BSE
  Outcome of the Fund-raising Committee meeting approving the allotment of 17058082 Equity shares
• Routine15 22 Oct, 18:28 · BSE
  Update on Trading Window Closure period
• Fund raising50 22 Oct, 13:25 · BSE
  Intimation of closure of the Issue period of the Rights Issue of NATCO Pharma Limited (the "Company")
• General75 19 Oct, 14:25 · BSE
  Natco Pharma announces launch of Carboplatin Injection (generic of Paraplatin) in the U.S. market
• Routine15 16 Oct, 17:03 · BSE
  Compliance Certificate under Reg.74(5) of SEBI(DP) Regulations, 2018

Shown 15 minutes after publication. Real time with Pro.